UK is no longer a draw to US pharma execs because of Brexit finds Alacrita

Ready for Brexit is independent and objective. It aims to help businesses and organisations manage the challenges and opportunities that Brexit brings.See member benefits 〉

(Shutterstock)

International life sciences consultancy Alacrita surveyed C-suite biotech executives in pre-eminent US companies and found that most feel that Brexit will make the UK a less attractive market. Anna Tobin reports

The Alacrita survey looked at how US pharmaceutical executives viewed the UK and the EU markets in the light of Brexit. It found that five to ten years after Brexit, over half, 52%, of US pharmaceutical executives feel that the UK will be a worse place for clinical trials and 69% feel that it will be a less attractive base for setting up a European head office.

The survey also reported that currently, the UK is the preferred EU country for clinical trials and also the top choice when it comes to choosing where to base an EU head office. It is second to Germany when it comes to the best country for launching a new pharmaceutical product.

Secure Payments using

Brexit Membership

Cookies

This site uses cookies to help provide a better user experience. If you wish to disable cookies in your browser, consult the Help section of your browser or go to www.aboutcookies.org.uk for guidance for all modern browsers. Privacy Policy